GeoVax Labs, Inc. announced that senior management will participate in investor and partner engagements during Biotech Showcase 2026 and the 44th Annual J.P. Morgan Healthcare Conference Week in San Francisco from January 12-15, 2026. During these premier investor forums, GeoVax leadership will highlight the company's 2025 operational achievements, clinical pipeline progress, and strategic priorities for 2026.
The presentation will cover key clinical catalysts, regulatory milestones, and business development related to multiple programs. For CM04S1, the company's COVID-19 vaccine candidate, management will discuss clinical status, translational data, and regulatory pathways for high-risk and immunocompromised populations. This program is currently in three Phase 2 clinical trials, being evaluated as a primary vaccine for immunocompromised patients and as a booster in specific patient populations.
Regarding Gedeptin®, the company's solid tumor therapy, GeoVax will present translational and clinical data supporting development in head and neck cancer and other high-value solid tumor indications. The therapy recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. For GEO-MVA, the vaccine targeting Mpox and smallpox, the company will discuss regulatory progress, clinical strategy, and potential registration pathways supporting civilian and biodefense use. Based on recent EMA regulatory guidance, GeoVax anticipates progressing directly to a Phase 3 clinical evaluation for this program.
The company will also highlight advancements in its manufacturing platform, specifically continuous cell-line manufacturing enabling scalable, resilient, and domestic vaccine production. Business development opportunities for partnership and collaboration to support pipeline advancement and long-term value creation will be another focus area. David Dodd, Chairman and CEO of GeoVax Labs, will present on January 13, 2026, at 2:30 pm PST at the Hilton Union Square in San Francisco.
GeoVax's presentation will be webcast live and may be accessed through the Events & Presentations section of the company's website. The webcast will be archived and available for replay for approximately one month following the event. Management will also host one-on-one investor and partner meetings throughout the conference to discuss GeoVax's progress across its diverse pipeline.
"We are pleased to share GeoVax's 2025 achievements with the global investor and biotech community at Biotech Showcase and the J.P. Morgan Healthcare Conference," said David Dodd. "Our team has delivered meaningful clinical and operational progress, strengthened our strategic position, and advanced multiple programs toward key inflection points in 2026. We look forward to engaging with shareholders, partners, and prospective collaborators on our differentiated pipeline and long-term growth strategy."
The company's participation in these high-profile conferences represents an important opportunity to communicate progress across its clinical-stage biotechnology portfolio. For investors and industry observers, these presentations provide insight into the company's trajectory across infectious disease vaccines and cancer therapies. The detailed updates on regulatory pathways and clinical strategies offer valuable information about potential milestones that could impact patient care and public health preparedness in coming years.
